> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Chiesi USA’s Bronchitrol
- URL: https://www.fdaweb.com/fda-approves-chiesi-usas-bronchitrol/
- Published: 2020-11-05T12:00:00.000Z
- Updated: 2026-09-14T16:35:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148029

FDA has approved Chiesi USA’s Bronchitrol (mannitol) inhalation powder, described as the first and only inhaled dry powder indicated as add-on maintenance therapy to improve pulmonary function in cystic fibrosis patients age 18 and older. A company [statement](https://www.marketwatch.com/press-release/chiesi-usa-inc-announces-fda-approval-of-bronchitolr-mannitol-inhalation-powder-2020-11-02?tesla=y&ref=fdaweb.com) says that in three clinical trials totaling 761 patients age 18 and older, Bronchitrol use led to a sustained improvement in forced expiratory volume versus control. The most common adverse reactions are said to be cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.